by Kevin Dooley, MD | Aug 8, 2023 | News and Information
We Need Your Help Are you frustrated that medical science knows so little about inclusion body myositis? Do you wish that more pharmaceutical companies would fund clinical drug trials for IBM? You can help! The INSPIRE-IBM natural history study needs patients. If you... 
by Kevin Dooley, MD | Sep 8, 2022 | News and Information
Medicare Policy and Wheelchair Seat Elevators Medicare is re-evaluating its policy of denying coverage for seat elevating systems for power wheelchairs, and is seeking public comments. If you live in the United States and have an interest in IBM, your input is needed!... 
by Kevin Dooley, MD | Jul 4, 2021 | News and Information
The IndeeLift The IndeeLift is a lifting device that has now been modified to meet the needs of people with inclusion body myositis. Its primary purpose is to raise people up from the ground after they have fallen, but it has many other uses. The IndeeLift and Falls... 
by Kevin Dooley, MD | Mar 30, 2021 | News and Information
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success.... 
by Kevin Dooley, MD | Aug 26, 2020 | News and Information
The Orphan Disease Center 2020 Million Dollar Bike Ride Grant Program is offering a $68,245 grant for the study of inclusion body myositis (IBM). Researchers from around the world are eligible to apply. Letters of Interest are due Friday, September 18. The grant is...